BM, MRCP, PhD

Training and education

University of Southampton School of Medicine
Medical oncology specialist registrar rotation, Wessex region

Fellowships

Clinical research fellow in medical oncology, Cancer Research UK, 2007 to 2010.

Experience

Dr Wheater is a consultant medical oncologist who has worked for the Trust since August 2011.

He completed specialist training in medical oncology in Bristol, Southampton and Portsmouth, between 2004 and 2011.

Key achievements

PhD in molecular biology of breast and kidney cancers.
Chief investigator for a national chemotherapy trial for relapsed germ cell cancers (Gem-TIP).

Research

Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma. Ann Surg Oncol. 2025 Jul;32(7):4976-4988. doi: 10.1245/s10434-025-17231-x. Epub 2025 Apr 7. PMID: 40192993; PMCID: PMC12130151.
Carter TJ, Broadfoot J, Coupland SE, Damato B, Evans H, Fenwick S, Khoja L, Krausa T, Lewis R, Nathan P, Modi S, Negretti G, Rashid S, Sacco JJ, Shaw H, Sisley K, Sowton R, Turajlic S, Turnbull N, Woraker A, Wheater M. Uveal Melanoma UK national guidelines: 2023 update. Eur J Cancer. 2025 Oct 1;228:115687. doi: 10.1016/j.ejca.2025.115687. Epub 2025 Aug 5. PMID: 40885127.
Geldart T, Pickering L, Sharma A, Wheater M, Scott D, Parikh O, Coleman S, Dhokia P, Hale MJ, Vaz L. A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab. Future Oncol. 2025 Dec;21(30):3947-3956. doi: 10.1080/14796694.2025.2595686. Epub 2025 Dec 12. PMID: 41385340; PMCID: PMC12758230.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Gschnell M, Dummer R, Arance A, Fenwick SW, Sacco JJ, John J, Wheater M, Ottensmeier CH. Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma. J Cancer Res Clin Oncol. 2025 Dec 29;152(1):25. doi: 10.1007/s00432-025-06291-x. PMID: 41461960; PMCID: PMC12748326.
Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma.
Vigneswaran G, Malalasekera W, Smith V, Gibson T, Patel S, Wheater M, Karydis I, Gupta S, Stedman B, Modi S.Melanoma Res. 2024 Apr 1;34(2):193-197. doi: 10.1097/CMR.0000000000000947. Epub 2023 Dec 1.PMID: 38051786
Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.
Mehta I, Dayimu A, Kumar S, Boobier C, Oladipo O, Burke D, Olson-Brown A, Yesildag P, Nobes J, Brown S, Booth C, Wheater M, Muller D, Fountain V, Ford L, Board R, McGurk L, Twelves S, Demiris N, Corrie P.Eur J Cancer. 2023 Nov;194:113344. doi: 10.1016/j.ejca.2023.113344. Epub 2023 Sep 17.PMID: 37804771
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators.Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13.PMID: 36796394
Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature.
Trivedi DB, Aldulaimi N, Karydis I, Wheater M, Modi S, Stedman B, Karavias D, Primrose J, Pearce N, Takhar AS.Melanoma Res. 2023 Feb 1;33(1):71-79. doi: 10.1097/CMR.0000000000000867. Epub 2022 Nov 21.
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
Modi S, Gibson T, Vigneswaran G, Patel S, Wheater M, Karydis I, Gupta S, Takhar A, Pearce N, Ottensmeier C, Stedman B.
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
Melanoma Res. 2022 Apr 1;32(2):103-111. doi: 10.1097/CMR.0000000000000806.PMID: 35254333